Navigation Links
Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
Date:12/12/2012

ycemic control has been demonstrated to reduce the onset and progression of these complications.

About Janssen Research & Development, LLC

Janssen Research & Development, LLC is headquartered in Raritan, N.J. and has affiliated facilities in Europe, the United States and Asia. Janssen Research & Development is leveraging a combination of internal and external innovation to discover and develop novel medicines and solutions in five distinct therapeutic areas: Neuroscience, Oncology, Immunology, Infectious Diseases and Vaccines, and Cardiovascular and Metabolism. For more information about Janssen Research & Development, LLC visit www.janssenrnd.com.  

Janssen Research & Development is part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Driven by our commitment to patients, we work together to bring innovative ideas, products, services and solutions to address serious unmet medical needs around the world.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health ca
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
10. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
11. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014   Ventana Medical ...  Group, today announced that its VENTANA System for ... in the European Union for routine pathology, including ... consisting of VENTANA Virtuoso software coupled with either ... HT slide scanner, provides automated digital slide creation, ...
(Date:8/20/2014)... CITY , Aug. 20, 2014 ApolloDx™ ... mobile diagnostic platform during a special event at the ... , on September 5, 2014. The event, which ... on the ApolloDx website, www.apollodx.com .    ... diagnostic testing," said Jared Bauer , Co-Founder and ...
(Date:8/20/2014)... DIEGO , Aug. 20, 2014 Trovagene, ... diagnostics, announced today that results from two clinical studies ... conference for the Company,s urine-based diagnostic test for the ... The IPV conference is scheduled to take place in ... to 25 th . Additionally, a new U.S. ...
Breaking Medicine Technology:Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3
... in Peer-Review Journal,Respiratory Medicine, SAN JOSE, Calif., ... Pulmonary Fibrosis (CPF) today announced a summary ... of the,largest databases of information on patients ... United States, was,published in Respiratory Medicine. The ...
... OBISPO, Calif.--(BUSINESS WIRE)--Mar 22, 2007 - FzioMed,Inc. announced ... on,novel, synthetic dermal fillers is being presented at ... March,22-24, 2007., In 2006, FzioMed launched Laresse Dermal ... the,company's patented polymer science. Laresse represents a completely,new ...
Cached Medicine Technology:Medical Journal Publishes First Large-Scale Survey Revealing,Experiences of IPF Patients 2Medical Journal Publishes First Large-Scale Survey Revealing,Experiences of IPF Patients 3Laresse Dermal Filler Research Presented at Anti-Aging World,Congress 2
(Date:8/20/2014)... 20, 2014 Botanica Day ... facial. Utilizing the new and popular stem cell ... fine lines and wrinkles and naturally repairs the ... highlighting the new service by offering clients a ... stem cell facial. , Pevonia® continues to be ...
(Date:8/20/2014)... -- Leaving the car at home and getting to work ... health, a new study indicates. Researchers looked at thousands ... percent of men and 72 percent of women drove to ... used public transit, and 14 percent of men and 17 ... to work weighed more and had higher levels of body ...
(Date:8/20/2014)... Chemically extracted acellular allogeneic nerve, from which ... have been removed, reduced postoperative immune rejection. ... neural substrates and base materials, such as ... can provide a good scaffold in the ... allogeneic nerve, similar to autologous nerve transplantation, ...
(Date:8/20/2014)... 20, 2014 Fresh from the cradle of ... sprung from the starting blocks. , Urbini, a new collection ... the Urbini Avi jogger to its lineup. , ... with a look inspired by the latest racing styles and ... , This versatile jogger offers a swift, smooth ride on ...
(Date:8/20/2014)... August 20, 2014 The National ... five-year, $1.24 million Science Education Partnership Award (SEPA) ... support NAHN’s collaborative project with the Hispanic Communications ... Careers. , This collaborative NIH R25 program has ... and linguistic diversity among health professionals by recruiting ...
Breaking Medicine News(10 mins):Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 3Health News:Want to Stay Slim? Leave the Car at Home 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3
... Irvine scientists will receive grants totaling $9.35 million to ... disease and traumatic brain injury. The grants from ... Oct. 21, to Dr. Henry Klassen, Leslie M. Thompson, ... the Sue and Bill Gross Stem Cell Research Center ...
... interdisciplinary approach to drug abuse and addiction research, The ... has been renewed as a "Center of Excellence" by ... National Institutes of Health. The designation comes with ... to further studies led by researchers and clinicians in ...
... University of California, San Diego School of Medicine indicates that ... plans that include parents and child, while at the same ... , The results were published today in the advanced online ... Boutelle, PhD, associate professor of pediatrics and psychiatry at UC ...
... (HealthDay News) -- A new study suggests that in women ... tissue in addition to a cancerous breast tumor is enough ... about how much of a "free margin" around a tumor ... the November issue of IJCP, the International Journal of ...
... A new research study conducted by Boston University ... significantly improve biennial mammography screening rates among inner city ... Journal of General Internal Medicine , indicate the importance ... patient populations. Breast cancer is the second ...
... , THURSDAY, Oct. 21 (HealthDay News) -- Over the ... in the United States will be 10 times greater ... that could affect cancer patients, access to treatment, according ... the number of patients requiring radiation therapy will increase ...
Cached Medicine News:Health News:UCI stem cell researchers to receive $9.35 million in state funding 2Health News:UCI stem cell researchers to receive $9.35 million in state funding 3Health News:UTHealth receives $11 million NIDA grant 2Health News:Parent-only treatment may be equally effective for children who are obese 2Health News:New Finding Suggests Safe Surgical Margins When Removing Breast Cancers 2Health News:BUSM study shows patient navigations improve mammography rates in minority women 2Health News:Demand for Radiation Therapy Predicted to Exceed Supply 2
The focus of HandEchart Professional is to offer a practical and basic electronic patient record keeping system that anyone can learn in minutes....
Archimedes is an innovative specialty calculator. Forget having to remember complicated formulas, just enter the values and out come the results....
A handy, quick reference for physicians, nurses, and other health care providers treating cancer patients....
A handy quick-reference tool for busy residents and clinicians with key facts and points essential for day-to-day patient care....
Medicine Products: